Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1195-1205

  Pimentel, Mark ^a   Morales, Walter ^a   Pokkunuri, Venkata ^a   Brikos, Constantinos ^a   Kim, Sun Moon ^a,b   Kim, Seong Eun ^a,c   Triantafyllou, Konstantinos ^d   Weitsman, Stacy ^a   Marsh, Zachary ^a   Marsh, Emily ^a   Chua, Kathleen S ^a   Srinivasan, Shanthi ^e   Barlow, Gillian M ^a   Chang, Christopher ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Konyang University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytolethal distending toxin; Irritable bowel syndrome; Small intestinal bacterial overgrowth; Vinculin

Indexed keywords

BACTERIAL TOXIN; BACTERIUM ANTIBODY; CYTOLETHAL DISTENDING TOXIN; VCL PROTEIN, HUMAN; VINCULIN; VINCULIN PROTEIN, RAT;

ANIMAL; AUTOIMMUNITY; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CROSS REACTION; DISEASE MODEL; ENTERITIS; GANGLION; HUMAN; IMMUNOLOGY; INNERVATION; INTERSTITIAL CELL OF CAJAL; INTESTINE INNERVATION; MICROBIOLOGY; MOUSE; PATHOGENICITY; PATHOPHYSIOLOGY; PHENOTYPE; RAT; SMALL INTESTINE;

ANIMALS; ANTIBODIES, BACTERIAL; AUTOIMMUNITY; BACTERIAL TOXINS; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENTERIC NERVOUS SYSTEM; ENTERITIS; GANGLIA; HUMANS; INTERSTITIAL CELLS OF CAJAL; INTESTINE, SMALL; MICE; PHENOTYPE; RATS; VINCULIN;

EID: 84937965074     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3435-5     Document Type: Article

References (58)

1. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40:1–10.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:712 e714–721 e714.
3. Lembo A. The clinical and economic burden of irritable bowel syndrome. Pract Gastroenterol. 2007;20:3–9.
4. Cash B. Economic impact of irritable bowel syndrome: what does the future hold? Am J Manag Care. 2005;11:S4–S6.
5. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association; 2001.
6. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am. 2011;40:11–19.
7. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:II43–II47.
8. Drossman DA, Richter JE, Talley NJ, Corazziari E, Thompson WG, Whitehead WE. Functional gastrointestinal disorders. Boston: Little Brown; 1994.
9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
10. Rome Foundation. Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006;15:307–312.
11. Kruis W, Thieme C, Weinzierl M, Schussler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology. 1984;87:1–7.
12. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2:653–654.
13. Pimentel M, Hwang L, Melmed GY, et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA-IBS diagnostic strategy. Dig Dis Sci. 2010;55:145–149.
14. Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141–146.
15. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334–340.
16. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–3506.
17. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.
18. Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157–1160.
19. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52:89–95.
20. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci. 2007;52:139–142.
21. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.
22. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329.
23. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
24. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–811.
25. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98–104.
26. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774–1778.
27. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with shigella infection. J Gastroenterol Hepatol. 2005;20:381–386.
28. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome—a meta-analysis. Am J Gastroenterol. 2006;101:1894–1899. quiz 1942.
29. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535–544.
30. Tauxe RV. Epidemiology of Campylobacter jejuni infections in the united states and other industrialized nations. In: Nachamkin I, Blaser MJ, Tompkins LS, eds. Campylobacter jejuni: Current and Future Trends. Washington: American Society for Microbiology; 1992:9–12.
31. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53:982–989.
32. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–1166.
33. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–2643.
34. Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, et al. The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats. Ann Surg. 1998;228:188–193.
35. Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16:3680–3686.
36. Pokkunuri V, Pimentel M, Morales W, et al. Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:434–442.
37. Sung J, Morales W, Kim G, et al. Effect of repeated Campylobacter jejuni infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. Neurogastroenterol Motil. 2013;25:529–537.
38. Der-Silaphet T, Malysz J, Hagel S, Larry Arsenault A, Huizinga JD. Interstitial cells of Cajal direct normal propulsive contractile activity in the mouse small intestine. Gastroenterology. 1998;114:724–736.
39. Malysz J, Thuneberg L, Mikkelsen HB, Huizinga JD. Action potential generation in the small intestine of w mutant mice that lack interstitial cells of Cajal. Am J Physiol. 1996;271:G387–G399.
40. Langton P, Ward SM, Carl A, Norell MA, Sanders KM. Spontaneous electrical activity of interstitial cells of Cajal isolated from canine proximal colon. Proc Natl Acad Sci USA. 1989;86:7280–7284.
41. Ordog T, Ward SM, Sanders KM. Interstitial cells of Cajal generate electrical slow waves in the murine stomach. J Physiol. 1999;518:257–269.
42. Streutker CJ, Huizinga JD, Campbell F, Ho J, Riddell RH. Loss of cd117 (c-kit)- and cd34-positive ICC and associated cd34-positive fibroblasts defines a subpopulation of chronic intestinal pseudo-obstruction. Am J Surg Pathol. 2003;27:228–235.
43. Vanderwinden JM, Liu H, De Laet MH, Vanderhaeghen JJ. Study of the interstitial cells of Cajal in infantile hypertrophic pyloric stenosis. Gastroenterology. 1996;111:279–288.
44. Ordog T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes. 2000;49:1731–1739.
45. Bassotti G, Villanacci V, Maurer CA, et al. The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation. Gut. 2006;55:41–46.
46. Torihashi S, Ward SM, Nishikawa S, Nishi K, Kobayashi S, Sanders KM. C-kit-dependent development of interstitial cells and electrical activity in the murine gastrointestinal tract. Cell Tissue Res. 1995;280:97–111.
47. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445–450. quiz 660.
48. Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:200–204.
49. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 2011;46:164–174.
50. Wood JD, Liu S, Drossman DA, Ringel Y, Whitehead W. Anti-enteric neuronal antibodies and the irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:78–85.
51. Peng X, Cuff LE, Lawton CD, DeMali KA. Vinculin regulates cell-surface e-cadherin expression by binding to beta-catenin. J Cell Sci. 2010;123:567–577.
52. Peng X, Nelson ES, Maiers JL, DeMali KA. New insights into vinculin function and regulation. Int Rev Cell Mol Biol. 2011;287:191–231.
53. Demali KA. Vinculin—a dynamic regulator of cell adhesion. Trends Biochem Sci. 2004;29:565–567.
54. Shen K, Tolbert CE, Guilluy C, et al. The vinculin c-terminal hairpin mediates f-actin bundle formation, focal adhesion, and cell mechanical properties. J Biol Chem. 2011;286:45103–45115.
55. Zemljic-Harpf AE, Ponrartana S, Avalos RT, et al. Heterozygous inactivation of the vinculin gene predisposes to stress-induced cardiomyopathy. Am J Pathol. 2004;165:1033–1044.
56. Varon C, Mocan I, Mihi B, et al. Helicobacter pullorum cytolethal distending toxin targets vinculin and cortactin and triggers formation of lamellipodia in intestinal epithelial cells. J Infect Dis. 2014;209:588–599.
57. Izard T, Tran Van Nhieu G, Bois PR. Shigella applies molecular mimicry to subvert vinculin and invade host cells. J Cell Biol. 2006;175:465–475.
58. Park H, Lee JH, Gouin E, Cossart P, Izard T. The rickettsia surface cell antigen 4 applies mimicry to bind to and activate vinculin. J Biol Chem. 2011;286:35096–35103.